Bromocriptine and CF 25-397 in the treatment of tardive dyskinesia.
Dopamine agonist therapy using selected drugs at particular dosage levels has been found to have therapeutic benefit in certain dyskinetic syndromes. Two ergot derivatives with dopamine agonist properties were administered at relatively low doses to eight neuroleptic-free schizophrenic patients with tardive dyskinesia. Neither agent significantly improved dyskinetic symptoms; no symptoms worsened. Dopamine agonists likely vary in their selective activation of functionally distinct dopamine receptors.
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects; D001971:Bromocriptine / Q000627:therapeutic use*; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D011725:Pyridines / Q000627:therapeutic use
D014150:Antipsychotic Agents; D004873:Ergolines; D011725:Pyridines; D001971:Bromocriptine; C012145:CF 25397